Patents Assigned to Upjohn
  • Patent number: 6821970
    Abstract: The present invention provides oxazinocarbazole derivatives having a ring connecting position 8 (C-8) and position 9 (N-9), and more specifically, provides compounds of formula (I) wherein R1, R2, R3 and R4 are described herein. These compounds are 5-HT ligands, and are useful for treating diseases wherein modulation of 5-HT activity is desired.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: November 23, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventor: Ruth Elizabeth TenBrink
  • Patent number: 6821969
    Abstract: The present invention provides a compound of formula I These compounds are useful as antiviral agents, in particular, as agents against viruses of the herpes family.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: November 23, 2004
    Assignee: Pharmacia & UpJohn Company
    Inventor: Atli Thorarensen
  • Patent number: 6818413
    Abstract: The invention relates to novel fluorescence-based assays for protein kinases and phosphatases which can be used in high throughput screening. The methods of the invention utilize a competitive immunoassay to determine the amount of substrate that is phosphorylated or dephosphorylated during the course of a kinase or phosphatase reaction to yield a product, as well as the phosphorylating or dephosphorylating activity of a kinase or phosphatase.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: November 16, 2004
    Assignee: Pharmacia and Upjohn Company
    Inventors: Dennis E. Epps, Charles K. Marschke
  • Patent number: 6814319
    Abstract: There is provided a process for reducing particle size of a drug, the process comprising (a) a step of dispersing about 10 g or less of the drug in a suitable volume of a liquid dispersion medium to form a suspension; (b) a step of bringing together in a vessel grinding media, magnetically activatable means for stirring and the suspension; (c) a step of magnetically activating the means for stirring to effect milling of the suspension to a weight average particle size not greater than about 1 &mgr;m; and (d) a step of separating the resulting milled suspension from the grinding media and the magnetically activatable means for stirring.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: November 9, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventor: Royal J. Haskell
  • Publication number: 20040214825
    Abstract: The present invention is a method of treating sexual disturbances in humans and inducing mating in non-human mammals using the compounds of formula (A) 1
    Type: Application
    Filed: May 24, 2004
    Publication date: October 28, 2004
    Applicant: Pharmacia & Upjohn Company
    Inventors: Robert B. McCall, Martin Durham Meglasson
  • Publication number: 20040215017
    Abstract: Substituted quinolone derivatives in which an oxazolidinone, isoxazolinone, or isoxazoline is covalently bonded to a quinolone, methods of using the quinolone derivatives, and pharmaceutical compositions containing the quinolone derivatives are disclosed. Methods of synthesizing these substituted quinolone derivatives are also disclosed, and in particular a method of manufacturing a 7-(2-oxo-1,3-oxazolidin-3-yl)aryl-3-quinolinecarboxylic acid by condensing a 4-(2-oxo-1,3-oxazolidin-5-yl)aryl boronic acid with a 7-halo-quinolone derivative. The quinolone derivatives possess antibacterial activity, and are effective against a number of human and veterinary pathogens in the treatment of bacterial diseases.
    Type: Application
    Filed: December 5, 2003
    Publication date: October 28, 2004
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventors: Mikhail F. Gordeev, Dinesh V. Patel, Michael R. Barbachyn, James R. Gage
  • Publication number: 20040214815
    Abstract: The present invention provides compounds of formula (I): 1
    Type: Application
    Filed: May 7, 2004
    Publication date: October 28, 2004
    Applicant: Pharmacia & Upjohn Company
    Inventors: William W. McWhorter, Valentina Badescu
  • Publication number: 20040214826
    Abstract: The present invention is a method of treating sexual disturbances in humans and inducing mating in non-human mammals using the compounds of formula (A) 1
    Type: Application
    Filed: May 24, 2004
    Publication date: October 28, 2004
    Applicant: Pharmacia & Upjohn Company
    Inventors: Robert M. McCall, Martin Durham Meglasson
  • Publication number: 20040214823
    Abstract: The present invention is a method of treating sexual disturbances in humans and inducing mating in non-human mammals using the compounds of formula (A) 1
    Type: Application
    Filed: May 14, 2004
    Publication date: October 28, 2004
    Applicant: Pharmacia & Upjohn Company
    Inventors: Robert B. McCall, Martin Durham Meglasson
  • Publication number: 20040214824
    Abstract: The present invention is a method of treating sexual disturbances in humans and inducing mating in non-human mammals using the compounds of formula (A) 1
    Type: Application
    Filed: May 24, 2004
    Publication date: October 28, 2004
    Applicant: Pharmacia & Upjohn Company
    Inventors: Robert B. McCall, Martin Durham Meglasson
  • Patent number: 6809112
    Abstract: The present invention is a method of treating sexual disturbances in humans and inducing mating in non-human mammals using the compounds of formula (A) in a dosage range where the sexually therapeutic amount is from about 0.2 thru 8 mg/person/dose and where the sexually mating amount is from about 0.003 thru 0.2 mg/kg/dose.
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: October 26, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Robert B. McCall, Martin Durham Meglasson
  • Publication number: 20040209925
    Abstract: The invention provides compounds of formula I: 1
    Type: Application
    Filed: November 26, 2003
    Publication date: October 21, 2004
    Applicants: ELAN PHARMACEUTICALS, INC., PHARMACIA & UPJOHN COMPANY
    Inventors: Shon R. Pulley, John A. Tucker
  • Patent number: 6797487
    Abstract: The present invention provides methods of reducing cellular production of amyloid beta (A&bgr;) from amyloid precursor protein (APP) by reducing Asp2 transcription or translation in cells.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: September 28, 2004
    Assignee: Pharamcia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 6796975
    Abstract: The present invention is a container for an IV aqueous solution of a Gram-positive oxazolidinone agent, such as linezolid a the compound of formula: which comprises having the container-solution contact surface material be a polyolefin.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: September 28, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Sandra M. Sims, Phil Bryan Bowman, Daniel C. Wade, Shri C. Valvani
  • Patent number: 6797834
    Abstract: The invention is a process for the preparation of a &Dgr;4,9-steroid of formula (II) which comprises contacting a &Dgr;5(10),9(11)-steroid of formula (I) with a phosphorous containing acid.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: September 28, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventor: Rajappa Vaidyanathan
  • Patent number: 6797003
    Abstract: An aspheric soft intraocular lens, having an optical power surface, which may have multiple radii portions or aspherical portions, as well as spherical portions, intended to replace the crystalline lens of a patient's eye, in particular after a cataract extraction. Such an aspheric soft lens is molded in a coined mold. A pair of core pins, positioned within the mold cavity during the lens forming process, will produce a pair of haptic-mounting holes within the lens. As the lenses are subsequently tumbled to remove flash, indentations will form adjacent to the haptic-mounting holes. These indentations allow for tangential attachment of the haptic to the lens which, in turn, enables maximum flexibility without exceeding the width of the optic.
    Type: Grant
    Filed: December 1, 1993
    Date of Patent: September 28, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Larry W. Blake, Lee T. Nordan
  • Patent number: 6794385
    Abstract: The present invention relates to a class of compounds represented by the formula (I) or a pharmaceutical acceptable salt, prodrug or ester thereof, pharmaceutical compositions comprising compounds of the formula (I), and methods of selectively inhibiting or antagonizing &agr;v&bgr;3 integrin.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: September 21, 2004
    Assignee: Pharmacia & Upjohn, S.p.A.
    Inventors: Paola Vianello, Tiziano Bandiera, Mario Varasi
  • Patent number: 6790610
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: September 14, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 6790950
    Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: September 14, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
  • Publication number: 20040171050
    Abstract: An unliganded form of Staphylococcus aureus thymidylate kinase (S. aureus TMK) has been crystallized, and the three dimensional x-ray crystal structure has been solved to 2.3 Å resolution. The x-ray crystal structure is useful for solving the structure of other molecules or molecular complexes, and designing inhibitors of S. aureus TMK activity.
    Type: Application
    Filed: January 8, 2004
    Publication date: September 2, 2004
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventor: Timothy E. Benson